In non-small cell lung cancer, breast cancer and esophageal cancer, MAGI2-AS3 played a key role in inhibiting cell proliferation and serving as a radiotherapy sensitizer 15-17; on the contrary, MAGI-AS3 functioned as an oncogenic potential in gastric cancer and colorectal cancer 9, 18. Here, MAGI2 is linked to breast cancer.